Merck partners up on T-cell tech platform in $374M autoimmune deal; Turnstone taps BMS vet Mike Burgess for top R&D role
→ Back at the beginning of the year, the team at Cue Biopharma brought its A round up to $26 million after building a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
